Changeflow GovPing Healthcare & Life Sciences OIG FAQs Clarify Stark Law vs Anti-Kickback Sta...
Routine Notice Added Final

OIG FAQs Clarify Stark Law vs Anti-Kickback Statute

Favicon for www.jdsupra.com JD Supra Healthcare
Detected
Email

Summary

HHS OIG published two new FAQs on April 23, 2026 (FAQ #4 and FAQ #17) addressing common misconceptions about the relationship between the physician self-referral law (Stark) and the Anti-Kickback Statute (AKS). The first FAQ clarifies that satisfying a Stark exception does not rebut AKS risk, as the statutes serve different purposes and have different intent requirements. The second FAQ clarifies that fair market value is only one element of an AKS safe harbor and cannot alone eliminate unlawful remuneration risk. OIG expressly rejects industry arguments to the contrary, citing consistency with statutory text, regulatory safe harbors, and decades of guidance. The FAQs reinforce OIG's long-standing position that healthcare arrangements must be evaluated under the totality of circumstances beyond technical Stark compliance or FMV benchmarks.

“Compliance with a Stark exception is not evidence that the parties lack AKS intent.”

Why this matters

Healthcare entities with physician financial arrangements should inventory existing arrangements that rely primarily on Stark exceptions and fair market value documentation. The OIG's explicit rejection of FMV-only compliance and its sporting-event example signal heightened scrutiny for nonmonetary compensation to referral sources. Particularly for arrangements involving entertainment, gifts, or compensation near the Stark nonmonetary compensation limit, counsel should assess whether the totality of circumstances, including intent indicators, supports AKS defensibility beyond the Stark exception analysis.

AI-drafted from the source document, validated against GovPing's analyst note standards . For the primary regulatory language, read the source document .
Published by Robinson+Cole on jdsupra.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

JD Supra is the legal industry's open library where US law firms publish client alerts and regulatory analysis. The Healthcare section aggregates everything from partners covering CMS reimbursement, HIPAA enforcement, FDA compliance, healthcare M&A, fraud and abuse, payer-provider disputes, telehealth, and the fast-moving state regulation of healthcare AI. Around 250 alerts a month. Watch this if you run a hospital legal department, advise digital health startups, manage payer compliance, or track how state Medicaid agencies and HHS-OIG actually enforce the rules they publish. The signal-to-noise ratio is genuinely good because firms only publish when they have something concrete to say to their clients. GovPing pulls each alert with the firm name, author, and topic.

What changed

OIG added two FAQs to its General Questions Regarding Certain Fraud and Abuse Authorities resource addressing the distinction between Stark Law compliance and Anti-Kickback Statute exposure. FAQ #4 clarifies that while Stark is a strict liability statute requiring no intent, AKS is intent-based; satisfying a Stark exception does not evidence lack of AKS intent and does not protect arrangements where remuneration is provided to induce or reward referrals. FAQ #17 clarifies that fair market value analysis, while important, is only one element of a safe harbor and cannot alone eliminate AKS risk.

Healthcare providers, hospitals, laboratories, and other entities operating under financial arrangements with referral sources should review existing and proposed arrangements through a dual lens. Technical compliance with a Stark exception or reliance on a fair market value benchmark, standing alone, does not provide AKS protection. Entities should assess commercial reasonableness and all circumstances of the arrangement including intent indicators, particularly for nonmonetary compensation such as entertainment or sporting event tickets.

Archived snapshot

Apr 25, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

April 24, 2026

OIG Reiterates a Core Message: Stark Compliance and Fair Market Value Alone Do Not Shield Against Anti-Kickback Statute Risk

Danielle Tangorre Robinson+Cole Health Law Diagnosis + Follow Contact LinkedIn Facebook X ;) Embed On April 23, 2026, the HHS Office of Inspector General (OIG) quietly—but pointedly—added two new FAQs to its “General Questions Regarding Certain Fraud and Abuse Authorities.” Although the principles articulated are not new, the timing and clarity of these FAQs reflect OIG’s continued effort to correct common—and risky—misunderstandings in the health care industry regarding the federal Anti‑Kickback Statute (AKS), the physician self‑referral law (“Stark”), and the role of fair market value (FMV) analyses. Together, these FAQs serve as a reminder that technical compliance with Stark or reliance on a fair market benchmark do not, standing alone, insulate an arrangement from AKS scrutiny.

The first new FAQ is FAQ #4: “Could a financial arrangement that satisfies an exception to the physician self-referral law (42 U.S.C. § 1395nn) violate the federal anti-kickback statute?” In its answer, OIG squarely addresses a persistent misconception that satisfying a Stark exception somehow rebuts AKS risk. OIG emphasizes several foundational points:

  • Stark and AKS serve different purposes, prohibit different conduct, and impose different consequences;
  • Stark is a strict liability statute; intent is irrelevant;
  • AKS is an intent‑based statute; knowing and willful intent to induce referrals is the core inquiry; and
  • Compliance with a Stark exception is not evidence that the parties lack AKS intent. Even where a financial arrangement “fits” squarely within a Stark exception, the arrangement may still violate AKS if one purpose of the remuneration is to induce or reward referrals. To illustrate this point, the OIG provides the “sporting event” example. It pointed out that hospitals, laboratories, or other providers may offer sporting event tickets or entertainment to referring physicians. OIG acknowledges that such arrangements might, depending on facts, technically satisfy the Stark exception for nonmonetary compensation under 42 C.F.R. § 411.357(k). However, OIG warns that these forms of remuneration are “unlikely to receive protection under any safe harbor to the federal anti-kickback statute” and therefore remain subject to totality‑of‑the‑circumstances review, including intent. Importantly, OIG reiterates its long‑standing position that providing remuneration to referral sources can violate AKS regardless of Stark compliance, a theme echoed in enforcement actions and advisory opinions over many years.

The second new FAQ is FAQ #17: “Can fair market value arrangements violate the federal anti-kickback statute?” **** This FAQ tackles another common compliance belief that fair market value may be the sole compliance cornerstone for AKS purposes. OIG again says no. While confirming that fair market value analyses are important and often one of the elements of a safe harbor, OIG stresses that fair market value is just one element and that compliance with a safe harbor requires meeting each element. As discussed in a prior podcast with the American Health Law Association, there are other factors that are important including commercial reasonableness.

OIG expressly rejects the industry argument that FMV eliminates unlawful remuneration, calling that position inconsistent with (i) the statutory text, (ii) the regulatory safe harbors, and (iii) decades of OIG guidance that OIG characterizes as “consistent and unwavering.”

Why These FAQs Matter Now

Although neither FAQ announces new law, their explicit pairing and contemporaneous release is notable. OIG appears focused on dispelling two closely related myths that continue to surface in enforcement matters:

  1. “We meet Stark, so AKS isn’t a problem.”
  2. “We paid fair market value, so there’s no kickback.” For entities in the healthcare space, these FAQs signal that you must look at the totality of the arrangement and ask the hard questions surrounding the relationship.

[View source.]

;) ;) Report

Latest Posts

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
Attorney Advertising.

©
Robinson+Cole Health Law Diagnosis

Written by:

Robinson+Cole Health Law Diagnosis Contact + Follow Danielle Tangorre + Follow more less

PUBLISH YOUR CONTENT ON JD SUPRA

  • ✔ Increased readership
  • ✔ Actionable analytics
  • ✔ Ongoing writing guidance Join more than 70,000 authors publishing their insights on JD Supra

Start Publishing »

Published In:

Anti-Kickback Statute + Follow Department of Health and Human Services (HHS) + Follow Fair Market Value + Follow Health Care Providers + Follow Healthcare Fraud + Follow New Guidance + Follow OIG + Follow Regulatory Oversight + Follow Risk Management + Follow Stark Law + Follow Administrative Agency + Follow General Business + Follow Health + Follow more less

Robinson+Cole Health Law Diagnosis on:

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra: Sign Up Log in ** By using the service, you signify your acceptance of JD Supra's Privacy Policy.* - hide - hide

CFR references

42 C.F.R. § 411.357(k)

Named provisions

FAQ #4: Stark Exception vs AKS FAQ #17: Fair Market Value vs AKS

Citations

42 U.S.C. § 1395nn Stark Law statutory reference
42 C.F.R. § 411.357(k) Stark nonmonetary compensation exception

Get daily alerts for JD Supra Healthcare

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from Robinson+Cole.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
Robinson+Cole
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Healthcare providers Medical device makers Pharmaceutical companies
Industry sector
6211 Healthcare Providers
Activity scope
Healthcare fraud compliance Physician referral arrangements Physician compensation structures
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Compliance
Topics
Anti-Money Laundering Employment & Labor Corporate Governance

Get alerts for this source

We'll email you when JD Supra Healthcare publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!